Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
triple-negative breast cancer
Pharma
Gilead’s Trodelvy nabs broad FDA approval in front-line TNBC
For now, approval in the PD-L1-positive population makes Trodelvy’s TNBC label broader than its rival. But AZ and Daiichi plan to catch up.
Angus Liu
Jun 24, 2026 5:00pm
AZ, Daiichi's Datroway approved in first-line TNBC
May 22, 2026 11:32am
ESMO: Datroway data edge out Trodelvy in first TROP2 face-off
Oct 19, 2025 2:30am
AZ, Daiichi's Datroway scores overall survival win in TNBC
Oct 6, 2025 10:48am
Gilead bolsters Trodelvy with first-line breast cancer win
May 31, 2025 8:00am
Gilead's Trodelvy chalks up another phase 3 breast cancer win
May 23, 2025 10:10am
